| PCP: from pharmacology to modelling schizophrenia BJ Morris, SM Cochran, JA Pratt Current opinion in pharmacology 5 (1), 101-106, 2005 | 359 | 2005 |
| Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs SM Cochran, M Kennedy, CE McKerchar, LJ Steward, JA Pratt, BJ Morris Neuropsychopharmacology 28 (2), 265-275, 2003 | 288 | 2003 |
| Neuropsychiatric Disease and Toxoplasma gondii Infection SA Henriquez, R Brett, J Alexander, J Pratt, CW Roberts Neuroimmunomodulation 16 (2), 122-133, 2009 | 269 | 2009 |
| Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap J Pratt, C Winchester, N Dawson, B Morris Nature reviews Drug discovery 11 (7), 560-579, 2012 | 203 | 2012 |
| Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia A Egerton, L Reid, CE McKerchar, BJ Morris, JA Pratt Psychopharmacology 179, 77-84, 2005 | 194 | 2005 |
| Cannabinoids and prefrontal cortical function: insights from preclinical studies A Egerton, C Allison, RR Brett, JA Pratt Neuroscience & Biobehavioral Reviews 30 (5), 680-695, 2006 | 189 | 2006 |
| Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence C Allison, JA Pratt Pharmacology & therapeutics 98 (2), 171-195, 2003 | 186 | 2003 |
| Role of training dose in discrimination of nicotine and related compounds by rats IP Stolerman, HS Garcha, JA Pratt, R Kumar Psychopharmacology 84, 413-419, 1984 | 185 | 1984 |
| Modelling prefrontal cortex deficits in schizophrenia: implications for treatment JA Pratt, C Winchester, A Egerton, SM Cochran, BJ Morris British journal of pharmacology 153 (S1), S465-S470, 2008 | 178 | 2008 |
| The neuroanatomical basis of anxiety JA Pratt Pharmacology & therapeutics 55 (2), 149-181, 1992 | 144 | 1992 |
| Discriminative stimulus properties of nicotine: further evidence for mediation at a cholinergic receptor JA Pratt, IP Stolerman, HS Garcha, V Giardini, C Feyerabend Psychopharmacology 81, 54-60, 1983 | 141 | 1983 |
| Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats A Egerton, L Reid, S McGregor, SM Cochran, BJ Morris, JA Pratt psychopharmacology 198, 37-49, 2008 | 137 | 2008 |
| Functional studies of specific imidazoline‐2 receptor ligands DJ Nutt, N French, S Handley, A Hudson, S Husbands, H Jackson, ... Annals of the New York Academy of Sciences 763 (1), 125-139, 1995 | 125 | 1995 |
| What can toxins tell us for drug discovery? AL Harvey, KN Bradley, SA Cochran, EG Rowan, JA Pratt, JA Quillfeldt, ... Toxicon 36 (11), 1635-1640, 1998 | 112 | 1998 |
| Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems N Dawson, BJ Morris, JA Pratt Schizophrenia bulletin 39 (2), 366-377, 2013 | 110 | 2013 |
| Characteristics of conditioned taste aversion produced by nicotine in rats. R Kumar, JA Pratt, IP Stolerman British Journal of Pharmacology 79 (1), 245, 1983 | 110 | 1983 |
| Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain SM Cochran, M Fujimura, BJ Morris, JA Pratt Synapse 46 (3), 206-214, 2002 | 108 | 2002 |
| Nicotine cue in rats analysed with drugs acting on cholinergic and 5-hydroxytryptamine mechanisms IP Stolerman, JA Pratt, HS Garcha, V Giardini, R Kumar Neuropharmacology 22 (9), 1029-1037, 1983 | 98 | 1983 |
| The thalamic reticular nucleus: a functional hub for thalamocortical network dysfunction in schizophrenia and a target for drug discovery JA Pratt, BJ Morris Journal of Psychopharmacology 29 (2), 127-137, 2015 | 86 | 2015 |
| Chronic handling modifies the anxiolytic effect of diazepam in the elevated plus-maze RR Brett, JA Pratt European journal of pharmacology 178 (1), 135-138, 1990 | 85 | 1990 |
